Medical News

RSS

NanoBio presents preclinical data of NB-201 for treating burn wounds at the 2009 ICAAC

NanoBio Corporation today announced compelling preclinical data for NB-201, a nanoemulsion-based topical lotion for the treatment of burn wounds. In preclinical studies, NB-201 dramatically reduced the severity of burn wound infections as well as inflammation following thermal injuries. The research was conducted at the University of Michigan Medical School in Ann Arbor as a collaborative effort between the University and NanoBio.

15 Sep 2009

MHPA to hold policy briefing on issues for Medicaid health plans in health reform

The Medicaid Health Plans of America (MHPA), the leading trade association solely focused on representing Medicaid health plans, is holding a policy briefing on issues for Medicaid health plans in health reform. Issues will include Medicaid expansion, prescription drug rebate equalization for Medicaid managed care, and medical loss ratios.

15 Sep 2009

Oil-and-water-based nanoemulsion could be more effective for treating burns

Treating second-degree burns with a nanoemulsion lotion sharply curbs bacterial growth and reduces inflammation that otherwise can jeopardize recovery, University of Michigan scientists have shown in initial laboratory studies.

15 Sep 2009

Dominion develops and validates clinical quantitative assays for tapentadol

Dominion Diagnostics (Dominion) has recently developed and validated one of the first clinical quantitative assays for the drug tapentadol (Nucynta(TM)) performed by liquid chromatography/tandem mass spectrometry (LC/MS/MS). Tapentadol, recently approved for use by the FDA, is a centrally-active analgesic that has demonstrated efficacy in pain relief with improved gastrointestinal tolerability compared to other opioids for pain management.

15 Sep 2009

Studies to focus on treatments for traumatic battlefield injuries

The University of Maryland R Adams Cowley Shock Trauma Center in Baltimore, Md., will serve as one of 12 core clinical centers in a newly established Extremity Trauma Clinical Research Consortium funded by the U.S. Department of Defense.

15 Sep 2009

Medline Industries launches Generation Pink powder-free synthetic exam gloves

As part of its ongoing campaign to raise breast cancer awareness, Medline Industries, Inc., the nation's largest privately held manufacturer and distributor of medical supplies, today announced the launch of its "Generation Pink powder-free synthetic exam glove.

15 Sep 2009

New 'adjuvant' developed by scientists could allow the creation of important new vaccines

Scientists at Oregon State University have developed a new "adjuvant" that could allow the creation of important new vaccines, possibly become a universal vaccine carrier and help medical experts tackle many diseases more effectively.

15 Sep 2009

Pesticide exposure is linked to Parkinson's disease

Individuals whose occupation involves contact with pesticides appear to have an increased risk of having Parkinson's disease, according to a report in the September issue of Archives of Neurology, one of the JAMA/Archives journals.

15 Sep 2009

Phase II clinical study results of Kamada's inhaled-AAT for cystic fibrosis presented at the ERS Congress

Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that data on its next-generation alpha-1 antitrypsin (Inhaled-AAT) in cystic fibrosis patients was presented today, at the Annual Congress of the European Respiratory Society (ERS) 2009, Vienna. As previously reported, the study showed that inhaled-AAT was safe and biologically effective.

15 Sep 2009

Limited health literacy linked with poorer access to health information

People who struggle with poor reading and math skills experience problems understanding instructions from health care providers and adhering to treatment, according to a new research review.

15 Sep 2009

miR-200 supression shifts primary lung cancer to metastatic disease

Primary lung cancer shifts to metastatic disease by suppressing a family of small molecules that normally locks the tumor in a noninvasive state, researchers at The University of Texas M. D. Anderson Cancer Center report in the Sept. 15 edition of Genes and Development.

15 Sep 2009

MonaVie to introduce healthful fruit drink in Poland

MonaVie (www.monavie.com), a leading international nutritional beverage company, today announces that it is entering the Polish market, and will be among the first to introduce a healthful fruit drink featuring the Brazilian acai (pronounced ah-SIGH-ee) berry.

15 Sep 2009

CTIA issues statement on the health effects of mobile usage

Today, CTIA-The Wireless Association® President and CEO Steve Largent issued the following statement in response to the U.S. Senate Subcommittee on Appropriations for the Departments of Labor, Health and Human Services, Education, and Related Agencies Hearing on “The Health Effects of Cell Phone Use:”

15 Sep 2009

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria

NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

15 Sep 2009

HFSA's annual scientific meeting features four late breaking clinical trials

The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured four late breaking clinical trials at the Hynes Convention Center in Boston.

15 Sep 2009

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.

15 Sep 2009

MedAssurant to support AHIP's focus on evidence-based healthcare initiatives

America's Health Insurance Plans (AHIP) and MedAssurant, Inc., announced today that MedAssurant, through its healthcare data analytics services, will support AHIP's research capabilities in the areas of quality and effectiveness of treatments.

15 Sep 2009

Rib-X and NIAID collaborate to develop an antibiotic treatment for N. gonorrhoeae

Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of multi-antibiotic resistant infections, today announced that it intends to enter into a Clinical Trials Agreement with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services.

15 Sep 2009

38 states and Puerto Rico to receive HHS grant for increasing adoptions

The U.S. Department of Health and Human Services (HHS) today awarded $35 million to 38 states and Puerto Rico for increasing the number of children adopted from foster care. States use the funds from the adoption incentive award to enhance their programs for abused and neglected children.

15 Sep 2009

CAP Cares program to preserve doctor-patient relationship

The Cooperative of American Physicians, Inc. (CAP) today announced that it has launched CAP Cares, a program created to help its physician members preserve the doctor-patient relationship in the wake of an adverse patient outcome.

15 Sep 2009